TMO Stock Recent News

Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and Salesforce could net significant returns, with an average gain estimate of 28.85%. Two standout "safer" stocks, AT&T and Annaly Capital, meet the dogcatcher ideal, offering high yields relative to their prices.

Thermo Fisher Scientific's Q4'24 and FY'24 results exceeded expectations, with revenue and profitability growing, positioning it for a potential 12% IRR long-term. Strong capital allocation, including $4.6 billion returned to shareholders and strategic acquisitions, supports Thermo Fisher's growth and undervalued stock potential. Despite weak guidance, Thermo Fisher's leadership in life sciences and pharma, along with expected 11% CAGR earnings growth, indicates a solid long-term outlook.

Daniel Loeb is a brilliant billionaire investor who's invested in all sorts of market environments.

If you're buying stocks for their dividend payments, it's important to focus on companies that also increase those payments. This can enable you to earn rising dividend income that offsets the effects of inflation.

Thermo Fisher Scientific Inc. (NYSE:TMO ) TD Cowen 45th Annual Health Care Conference Call March 3, 2025 9:10 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Well, welcome to the 45th Annual TD Cowen Healthcare Conference.

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE: TMO) (“Thermo Fisher”). Trian issued the following statement:

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the CorEvitas Systemic Lupus Erythematosus Registry.

Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and filtration business for about $4.1 billion.

Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for debt paydown ST. PAUL, Minn.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that the company has entered into a definitive agreement with Solventum (NYSE: SOLV) to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as i.